Skip to content

Xeris Biopharma Holdings, Inc. XERS Amortization of capitalized software and acquired intangible assets

Amortization of capitalized software and acquired intangible assets at other companies

Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO

Other financials

Income statement

See full
Revenue$83.1M+38.3%
Gross profit$72.6M+41.2%
Operating income$7.9M+356%
Net income$2.2M+124%
EPS (diluted)$0.01+117%

Balance sheet

See full
Cash & equivalents$111.8M+91.2%
Total debt$258.6M-3.8%
Total equity$13.0M+137%
Total assets$392.0M+24.3%

Cash flow

See full
Operating cash flow$9.9M+198%
CapEx$131.0K
Free cash flow-$29.1M

Valuation

See full
Market cap$1.28B+18.3%
Enterprise value$1.42B+8.7%
P/E106.4×
P/S4.1×-0.8×

Profitability

See full
Gross margin85.9%+3.7pp
Operating margin11.4%+7.7pp
Net margin3.8%+2.1pp

Returns & leverage

See full
Return on equity-209.8%
Debt / equity19.9×
Current ratio2.1×+0.4×

Where this comes from

Reported directly by Xeris Biopharma Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.

The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xeris Biopharma Holdings, Inc.'s amortization of capitalized software and acquired intangible assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xeris Biopharma Holdings, Inc.'s amortization of capitalized software and acquired intangible assets?
Xeris Biopharma Holdings, Inc. (XERS) reported amortization of capitalized software and acquired intangible assets of $2.71M in Q1 2026.
How has Xeris Biopharma Holdings, Inc.'s amortization of capitalized software and acquired intangible assets changed year-over-year?
Xeris Biopharma Holdings, Inc.'s amortization of capitalized software and acquired intangible assets decreased by 0.0% year-over-year, from $2.71M to $2.71M.
What is the long-term trend for Xeris Biopharma Holdings, Inc.'s amortization of capitalized software and acquired intangible assets?
Over 4 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s amortization of capitalized software and acquired intangible assets has grown at a 110.7% compound annual growth rate (CAGR), from $550K to $10.84M.